Ponatinib hydrochloride is a potent, orally available multi-targeted inhibitor of Pan BCR-ABL kinase. It potently inhibits ABL with an IC50 of 0.37 nM, also inhibits SRC , VEGFR2, FGFR1, PDGFRα, LYN with an IC50s of 5.4 nM, 1.5 nM, 2.2 nM, 1.1 nM, 0.24 nM respectively and exhibits significant potential in cancer reserach.

Cholesteryl hemisuccinate is a cholesterol derivative and a potent inhibior of DNA polymerase and DNA topoisomerase with an IC50 of 2.9 μM, 6.3 μM, 25 μM for Rat DNA polymerase β, Human DNA polymerase λ and Human DNA topoisomerase I respectively. It exhibits anticancer effect due to its ability to inhibit DNA replication, repair and […]

Cholesteryl hemisuccinate is a cholesterol derivative and a potent inhibior of DNA polymerase and DNA topoisomerase with an IC50 of 2.9 μM, 6.3 μM, 25 μM for Rat DNA polymerase β, Human DNA polymerase λ and Human DNA topoisomerase I respectively. It exhibits anticancer effect due to its ability to inhibit DNA replication, repair and […]

SD-2301 is a potent and selective PROTAC-based STAT3 degrader that targets the VHL–cullin 2 complex, enhancing dendritic cell function and anti-tumor immunity. It synergizes with anti-PD-L1 therapy to robustly suppress tumor growth in vivo.

SD-2301 is a potent and selective PROTAC-based STAT3 degrader that targets the VHL–cullin 2 complex, enhancing dendritic cell function and anti-tumor immunity. It synergizes with anti-PD-L1 therapy to robustly suppress tumor growth in vivo.

SD-2301 is a potent and selective PROTAC-based STAT3 degrader that targets the VHL–cullin 2 complex, enhancing dendritic cell function and anti-tumor immunity. It synergizes with anti-PD-L1 therapy to robustly suppress tumor growth in vivo.